Biofidelity Revolutionising genomic analysis
3 known investors
Biofidelity develops genomic biomarker testing technologies—its Aspyre and Enspyre products—for cancer detection, treatment selection, and minimal residual disease monitoring. The company serves oncology providers and patients with precision genomic diagnostics across the cancer patient journey.
Investors · 3
Frequently asked questions
- What does Biofidelity Revolutionising genomic analysis do?
- Biofidelity develops genomic biomarker testing technologies—its Aspyre and Enspyre products—for cancer detection, treatment selection, and minimal residual disease monitoring. The company serves oncology providers and patients with precision genomic diagnostics across the cancer patient journey.
- Who are Biofidelity Revolutionising genomic analysis's investors?
- Biofidelity Revolutionising genomic analysis's investors include Longwall Venture Partners LLP, Octopus Ventures, Perscitus LLP.